Eli Lilly, the maker of Ozempic, has developed a weight loss pill that could work as well. The new weight loss pill, orforglipron, is a once-daily oral GLP-1 receptor agonist that is designed to lower ...

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Ozempic can induce some rather unpleasant side effects, from feeling sick and bloated, to dizziness and even diarrhea.

Less expensive versions of popular weight-loss medications like Wegovy and Zepbound are soon going to be taken off the market ...

A recent study shows consistent users of Eli Lilly's new weight loss drug, Zepbound, have managed to keep the weight off.

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

A large-scale study involving Estonian scientists suggests that the benefits of weight-loss surgery may be partly determined ...

Novo Nordisk shares fell Tuesday after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. Shares fell as much as 9.8% in ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Looking for help burning fat and curbing your appetite? We compared the best w͏eight lo͏ss suppl͏ements, analyzing their ...

Eli Lilly reports positive late-stage data for its weight-loss pill. BMO analyst says Lilly's update will weigh on shares of ...

Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic ...